Exposure–response modelling of osimertinib in patients with non‐small cell lung cancer
British Journal of Clinical Pharmacology · 2024-12 · 90 (12) · 3263-3276
DOI: 10.1111/bcp.16199 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 19.08.2024. Verfasst von Martin Johnson und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Science, R&D, AstraZeneca, Cambridge, UK. Hauptthemen laut MEDLINE: Acrylamides, Carcinoma, Non-Small-Cell Lung, Aniline Compounds, Lung Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Aims
Osimertinib is a third‐generation, irreversible, central nervous system‐active, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with efficacy in EGFR‐mutated non‐small cell lung cancer (NSCLC). We assessed the relationship between plasma osimertinib levels and its efficacy and safety events.
Methods
Comprehensive pharmacokinetics exposure–response (E–R) modelling was performed utilizing steady state area under the curve (AUC ss ) data from first‐line, ≥second‐line and adjuvant studies from the osimertinib clinical development programme (20–240 mg once‐daily dosing; N = 1689 patients). Analyses were conducted for survival using a proportional hazard model; for interstitial lung disease (ILD) and left ventricular ejection fraction (LVEF) events using a penalized logistic regression model and graphical analysis of potential confounding factors; and for rash and diarrhoea events using descriptive analysis.
Results
E–R modelling analyses indicated no clear trend of increasing efficacy with increasing osimertinib AUC ss ; efficacy in all exposure quartiles was significantly better than the control arm (comparator EGFR‐TKI, chemotherapy or placebo) irrespective of treatment line. Model‐based analysis suggested a potential relationship between increased osimertinib exposure and increased probability of ILD events, predominantly in Japanese patients. Additionally, there were increased probabilities of rash or diarrhoea with increasing osimertinib exposure. The probability of LVEF events showed overlapping confidence intervals for osimertinib ≤80 mg and control.
Conclusions
E–R modelling in patients with EGFR‐mutated NSCLC demonstrated that increased osimertinib exposure was unlikely to increase efficacy but may increase occurrence of certain adverse events. Hence, long‐term treatment with doses ≥80 mg was not expected to provide additional benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Science, R&D, AstraZeneca, Cambridge, UK.
- Certara, Radnor, Pennsylvania, USA.
- IntiQuan GmbH, Basel, Switzerland.
- Oncology Biometrics, AstraZeneca, Cambridge, UK.
- Global Medicines Development, AstraZeneca, Cambridge, UK.
- Clinical Pharmacology and Safety Science, AstraZeneca, Waltham, Massachusetts, USA.
Förderung
- AstraZeneca
Zitieren
APA
Johnson, M., Lin, Y. W., Schmidt, H., Sunnaker, M., Van Maanen, E., Huang, X., Rukazenkov, Y., Tomkinson, H., & Vishwanathan, K. (2024). Exposure–response modelling of osimertinib in patients with non‐small cell lung cancer. British Journal of Clinical Pharmacology, 90(12), 3263-3276. https://doi.org/10.1111/bcp.16199
Vancouver
Johnson M, Lin YW, Schmidt H, Sunnaker M, Van Maanen E, Huang X, et al. Exposure–response modelling of osimertinib in patients with non‐small cell lung cancer. British Journal of Clinical Pharmacology. 2024;90(12):3263-3276. doi:10.1111/bcp.16199
BibTeX
@article{Johnson2024,
author = {Johnson, Martin and Lin, Yu-Wei and Schmidt, Henning and Sunnaker, Mikael and Van Maanen, Eline and Huang, Xiangning and Rukazenkov, Yuri and Tomkinson, Helen and Vishwanathan, Karthick},
title = {Exposure–response modelling of osimertinib in patients with non‐small cell lung cancer},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
volume = {90},
number = {12},
pages = {3263--3276},
doi = {10.1111/bcp.16199}
}
EUVIMED